Cargando…

Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients

Whilst calcineurin inhibitors (CNI) are the cornerstone of immunosuppressive maintenance therapy in kidney transplantation, several studies have investigated the safety of CNI withdrawal in order to avoid their numerous side effects. In this context, we performed several years ago a clinical randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Masset, Christophe, Dantal, Jacques, Soulillou, Jean-Paul, Walencik, Alexandre, Delbos, Florent, Brouard, Sophie, Giral, Magali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744190/
https://www.ncbi.nlm.nih.gov/pubmed/36518770
http://dx.doi.org/10.3389/fimmu.2022.1021481
_version_ 1784848866478129152
author Masset, Christophe
Dantal, Jacques
Soulillou, Jean-Paul
Walencik, Alexandre
Delbos, Florent
Brouard, Sophie
Giral, Magali
author_facet Masset, Christophe
Dantal, Jacques
Soulillou, Jean-Paul
Walencik, Alexandre
Delbos, Florent
Brouard, Sophie
Giral, Magali
author_sort Masset, Christophe
collection PubMed
description Whilst calcineurin inhibitors (CNI) are the cornerstone of immunosuppressive maintenance therapy in kidney transplantation, several studies have investigated the safety of CNI withdrawal in order to avoid their numerous side effects. In this context, we performed several years ago a clinical randomized trial evaluating CNI weaning in stable kidney transplant recipients without anti-HLA immunization. The trial was interrupted prematurely due to a high number of de novo DSA (dnDSA) and biopsy proven acute rejection (BPAR) in patients who underwent tacrolimus weaning, resulting in treatment for rejection and resumption of tacrolimus. We report here the long-term outcomes of patients included in this clinical trial. Ten years after randomization, all patients are alive with a functional allograft. They all receive tacrolimus therapy except one with recurrent cutaneous neoplasia issues. Long-term eGFR was comparable between patients of the two randomized groups (46.4 ml/min vs 42.8 ml/min). All dnDSA that occurred during the study period became non-detectable and all rejections episodes were reversed. The retrospective assessment of HLA DQ single molecule epitope mismatching determined that a majority of patients who developed dnDSA after tacrolimus withdrawal would have been considered at high immunological risk. Minimization of immunosuppression remains a challenging objective, mainly because of the issues to properly select very low immunological risk patients. Valuable improvements have been made the last decade regarding evaluation of the allograft rejection notably through the determination of numerous at-risk biomarkers. However, even if the impact of such tools still need to be clarify in clinical routine, they may permit an improvement in patients’ selection for immunosuppression minimization without increasing the risk of allograft rejection.
format Online
Article
Text
id pubmed-9744190
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97441902022-12-13 Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients Masset, Christophe Dantal, Jacques Soulillou, Jean-Paul Walencik, Alexandre Delbos, Florent Brouard, Sophie Giral, Magali Front Immunol Immunology Whilst calcineurin inhibitors (CNI) are the cornerstone of immunosuppressive maintenance therapy in kidney transplantation, several studies have investigated the safety of CNI withdrawal in order to avoid their numerous side effects. In this context, we performed several years ago a clinical randomized trial evaluating CNI weaning in stable kidney transplant recipients without anti-HLA immunization. The trial was interrupted prematurely due to a high number of de novo DSA (dnDSA) and biopsy proven acute rejection (BPAR) in patients who underwent tacrolimus weaning, resulting in treatment for rejection and resumption of tacrolimus. We report here the long-term outcomes of patients included in this clinical trial. Ten years after randomization, all patients are alive with a functional allograft. They all receive tacrolimus therapy except one with recurrent cutaneous neoplasia issues. Long-term eGFR was comparable between patients of the two randomized groups (46.4 ml/min vs 42.8 ml/min). All dnDSA that occurred during the study period became non-detectable and all rejections episodes were reversed. The retrospective assessment of HLA DQ single molecule epitope mismatching determined that a majority of patients who developed dnDSA after tacrolimus withdrawal would have been considered at high immunological risk. Minimization of immunosuppression remains a challenging objective, mainly because of the issues to properly select very low immunological risk patients. Valuable improvements have been made the last decade regarding evaluation of the allograft rejection notably through the determination of numerous at-risk biomarkers. However, even if the impact of such tools still need to be clarify in clinical routine, they may permit an improvement in patients’ selection for immunosuppression minimization without increasing the risk of allograft rejection. Frontiers Media S.A. 2022-11-28 /pmc/articles/PMC9744190/ /pubmed/36518770 http://dx.doi.org/10.3389/fimmu.2022.1021481 Text en Copyright © 2022 Masset, Dantal, Soulillou, Walencik, Delbos, Brouard, Giral and the Nantes DIVAT Consortium https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Masset, Christophe
Dantal, Jacques
Soulillou, Jean-Paul
Walencik, Alexandre
Delbos, Florent
Brouard, Sophie
Giral, Magali
Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients
title Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients
title_full Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients
title_fullStr Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients
title_full_unstemmed Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients
title_short Case Report: Long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients
title_sort case report: long-term observations from the tacrolimus weaning randomized clinical trial depicts the challenging aspects for determination of low-immunological risk patients
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744190/
https://www.ncbi.nlm.nih.gov/pubmed/36518770
http://dx.doi.org/10.3389/fimmu.2022.1021481
work_keys_str_mv AT massetchristophe casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients
AT dantaljacques casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients
AT soulilloujeanpaul casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients
AT walencikalexandre casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients
AT delbosflorent casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients
AT brouardsophie casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients
AT giralmagali casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients
AT casereportlongtermobservationsfromthetacrolimusweaningrandomizedclinicaltrialdepictsthechallengingaspectsfordeterminationoflowimmunologicalriskpatients